drugset
drugset / Trial / NCT04068272

Safety of Bosentan in Type II Diabetic Patients

NCT04068272 ↗

Phase 1 Completed 22 enrolled Retinset SL Instituto Universitario de Oftalmobiología Aplicada (Institute of Applied Ophthalmobiology) - IOBA · collab
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study evaluates the safety of topical Bosentan in Type II Diabetes patients

Timeline

Start
2019-09-07
Primary completion
2022-05-20
Completion
2022-05-20

Drugs

EvaluationDrugModalityDoseRoute
Subject Bosentan Other / unclassified 5 mg/ml Topical

Indications

diabetes mellitus